Document:

EX-10.9.2

 Exhibit 10.9.2 

CONFIDENTIAL EXECUTION VERSION 

OMNIBUS AMENDMENT AGREEMENT 

THIS OMNIBUS AMENDMENT AGREEMENT
(“Agreement”) is entered into and made effective as of October 3, 2014 (the “Effective Date”) by and between ARIAD PHARMACEUTICALS, INC., a Delaware corporation with its
principal place of business at 26 Landsdowne Street, Cambridge, MA 02139 (“ARIAD”), and BELLICUM PHARMACEUTICALS, INC., a Delaware corporation with a place of business at 2130
Holcombe Boulevard, Suite 850, Houston, TX 77030 (“Bellicum”). ARIAD and Bellicum may be referred to herein individually as a “Party” and collectively as “Parties.” 

WHEREAS, the Parties previously executed the following agreements: an Amended and Restated License Agreement, dated
March 7, 2011 (the “License Agreement”); an Investor Rights Agreement, dated July 25, 2006, as amended on March 25, 2009 (the “IRA”); and a Stock Purchase Agreement, dated July 25, 2006 (the
“SPA”) (collectively, these three agreements are referred to herein as the “Current Agreements”); and 

WHEREAS, the Parties wish to restructure and amend the Current Agreements in accordance with the terms and conditions
set forth herein, it being understood that certain provisions in the License Agreement are not being amended but may no longer be applicable. 

NOW THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein and
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, agree as follows: 
  

	1.	DEFINED TERMS. 

 1.1 Any capitalized term used but
not defined herein shall have the meaning ascribed to it under the Current Agreements. 
  

	2.	PROMISSORY NOTE. 

 2.1 Payments by Bellicum.
Bellicum will pay ARIAD Fifty Million US dollars ($50,000,000) in up to three installments pursuant to this Agreement and a promissory note that will be executed by the Parties contemporaneously with this Agreement (the “Note”).

 (a) The first payment by Bellicum, in the amount of Fifteen Million US dollars ($15,000,000); the “First
Payment”) shall be delivered to ARIAD on the Effective Date following execution of this Agreement. 
 (b) The second
payment by Bellicum, in the amount of Twenty Million US dollars ($20,000,000; the “Second Payment”), is due on June 30, 2015. 

(c) The third payment by Bellicum, in the amount of Fifteen Million US dollars ($15,000,000; the “Third Payment”), is
due on June 30, 2016. 
 Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the
Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  
 1 

 CONFIDENTIAL 

 
 (d) Although specific due dates are recited in subsections
(b) and (c) of this Section 2.1, Bellicum may prepay the Second Payment and/or the Third Payment at any time following the First Payment and prior to the applicable due date. 

2.2 Bellicum’s Other Obligations; Termination of the Note; Termination of this Agreement. Bellicum’s obligations for the
Second Payment and the Third Payment under the Note are absolute and unconditional, and such obligations of Bellicum are not affected by the expiration or termination of the Current Agreements (or any of them) and/or this Agreement, for any reason
other than the termination of both the License Agreement by Bellicum in accordance with Section 9.2 of the License Agreement and this Agreement by Bellicum in accordance with the penultimate sentence of this Section 2.2 for an
uncured material breach by ARIAD of at least one of the specific provisions of the License Agreement as listed and described in Exhibit B (attached hereto and incorporated herein; each a “Section 2.2 Material Breach”),
wherein each such Section 2.2 Material Breach, if uncured, would constitute grounds for termination of the License Agreement by Bellicum under Section 9.2 of the License Agreement. In the event of an uncured Section 2.2 Material
Breach, the Note will terminate upon delivery of written notice of termination by Bellicum to ARIAD referencing this Section 2.2, and thereafter the Note will have no further force or effect. In addition to automatic termination of this
Agreement as set forth in Section 3.2(d) hereof, each of Bellicum and ARIAD, as applicable, has the right to terminate this Agreement solely in the event such Party terminates the License Agreement in accordance with Section 9.2.1 of the
License Agreement based on an uncured material breach of the License Agreement by the other Party that would constitute grounds for termination under Section 9.2 of the License Agreement. For clarity, in the event of termination in accordance
with Section 9.2.1 of the License Agreement, Section 9.3 of the License Agreement (as amended hereby) shall apply. 
  

	3.	AMENDMENTS TO THE CURRENT AGREEMENTS. 

3.1 Upon First Payment. From and after the date of ARIAD’s receipt of the First Payment on the Effective Date: 

(a) Each of the defined terms Dimerizer, Licensed Field, Licensed Patent Rights, Licensed Product and [***] Analog, as set forth in the
License Agreement, is hereby deleted and replaced in its entirety with the following, corresponding new defined terms: 

“Dimerizer” shall mean any molecule that induces the interaction or proximity of two or more proteins, modified to contain a
dimerizer-binding domain, resulting in the activation of specific signaling, gene transcription, or protein secretion events in cultured cells, whole animals or humans. 

“Licensed Field” shall mean the treatment or prevention of the progression or occurrence of any disease, disorder or condition
in humans, other than a treatment or prevention achieved through an administration within the Excluded Field. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 2 

 CONFIDENTIAL 

 
 “Licensed Patent Rights” shall mean (a) all
Patent Rights Controlled by ARIAD as of the Original Effective Date or during the Primary License Term, which are necessary or useful for the development, manufacture, use, sale, offer for sale or import of Licensed Products or of Dimerizers used or
incorporated in Licensed Products, including without limitation Patent Rights covering the [***]-ARIAD MTA Technologies and (b) all Patent Rights whether or not controlled by ARIAD that are listed on Schedule A1 (“Homodimerizer Patent
Rights”) and Schedule A2 (“Heterodimerizer Patent Rights”), attached hereto and made a part hereof, regardless of the ownership of such Patent Rights. Schedule A3 sets forth Patent Rights under the [***]-ARIAD MTA
Technologies. Schedules A1, A2 and A3 shall be updated, as necessary, from time to time by ARIAD by written notice to Bellicum. 

“Licensed Product” shall mean any prophylactic or therapeutic product the manufacture, sale, import, administration,
activation or other use of which is covered by a claim of any Licensed Patent Rights or by Licensed Technology (including, without limitation, Patent Rights licensed or assigned to Bellicum that cover any of the [***]-ARIAD MTA Technologies), and
that (a) contains proteins or genes encoding proteins, the interaction or proximity of which proteins is induced by a Homodimerizer; (b) is a Homodimerizer for use with a product described in clause (a); or (c) is a treatment regimen
or process utilizing any product described in clause (a) or (b). The definition of Licensed Product expressly includes those products that are within the definition of Licensed Product on or prior to the effective date of the Omnibus Amendment.
For clarity, the term “Licensed Product,” as amended by the Omnibus Amendment, shall have the foregoing meaning until such time as the Third Payment (as defined in the Omnibus Amendment) has been made pursuant to the terms of the Omnibus
Amendment, and the term “Licensed Product” shall have the meaning set forth in Section 3.3(a) of the Omnibus Amendment after the Third Payment has been made pursuant to the terms of the Omnibus Amendment. 

“[***] Analog” shall mean a compound similar to [***] in [***]. 

and each of the following new defined terms (Academic MTA, Excluded Field, Heterodimerizer, Homodimerizer, Human Gene Therapy, MTA Technology
and Omnibus Amendment) is hereby inserted into Section 1 of the License Agreement in the appropriate alphabetical location: 

“Academic MTA” shall mean a material transfer agreement pursuant to which ARIAD provided a dimerizer or one or more genetic
constructs encoding a dimerizer binding protein to a researcher at an academic institution or at a not-for-profit entity. 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 3 

 CONFIDENTIAL 

 
 “Excluded Field” shall mean (1) Human Gene
Therapy and (2) regulation of the expression of proteins or other macromolecules [***]. 
 “Heterodimerizer”
shall mean a Dimerizer that contains two structurally and functionally distinct binding motifs, and that induces the interaction or proximity of proteins containing structurally and functionally different dimerizer-binding domains. By way of
non-limiting example, [***] Analogs are Heterodimerizers. 
 “Homodimerizer” shall mean a Dimerizer that contains two
structurally and functionally identical binding motifs, and that induces the interaction or proximity of proteins containing functionally identical dimerizer-binding domains. By way of non-limiting example, [***] is a Homodimerizer. 

“Human Gene Therapy” shall mean the in vivo administration of genetic material directly into a human being using viral
vectors, including but not limited to AAV Vectors, to transfer such material into the patient’s own cells for the purpose of producing proteins or other macromolecules that are expressed in or secreted from the transduced cells for therapeutic
or prophylactic purposes, where (i) the expression of such proteins or other macromolecules is regulated through the administration of [***] or another [***] Dimerizer, or (ii) the inserted genetic material is not regulated through the
administration of a Dimerizer. For clarity, “Human Gene Therapy” shall not include (a) any use where genetic material is inserted into a cell ex vivo, including without limitation any use for a cancer or non-cancer vaccine or
immunotherapeutic product or (b) any use where activation of genetic material for any function other than expression is regulated through the administration of Dimerizer. 

“MTA Technology” shall mean Homodimerizer and Heterodimerizer technology and related intellectual property rights related to
Licensed Products in the Licensed Field which have been licensed or otherwise conveyed to ARIAD under an Academic MTA and which ARIAD has the right to sublicense or otherwise convey to Bellicum hereunder.  

“Omnibus Amendment” shall mean the Omnibus Amendment Agreement, dated October 3, 2014, executed by the Parties.

 (b) Section 2.1.1 of the License Agreement is hereby deleted and replaced with the following:  

Grant of License. From and after the effective date of the Omnibus Amendment, ARIAD hereby grants to Bellicum an exclusive (even as to
ARIAD), fully-paid, irrevocable (unless this Agreement is terminated in accordance with the terms of the Omnibus Amendment) license, including the right to grant sublicenses in accordance with Section 2.1.4, under the Licensed Patent Rights and
Licensed 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 4 

 CONFIDENTIAL 

 
 
Technology and ARIAD’s interest in any Improvements, subject at all times to the restrictions and obligations under the [***] Agreement with respect to the [***] IP, (a) to research,
develop, test, obtain Regulatory Approval for, make, have made, use, have used, sell, offer for sale, have sold, import, have imported, export and have exported Licensed Products (including, without limitation, any Dimerizer included or utilized
therein) in the Territory, for any and all uses within the Licensed Field during the Term, subject to the terms and conditions of this Agreement, and (b) to research, develop, test, make, have made, use, import and export, in each case solely
for research purposes, including pre-clinical IND-enabling toxicology and other pre-clinical studies (but not to conduct clinical trials with respect to or to obtain Regulatory Approval for, sell or commercialize), a product that uses or
incorporates a Heterodimerizer in the Licensed Field. For clarity, from and after the Effective Date, the term “Licensed Technology” includes MTA Technology relevant to Homodimerizers in the Licensed Field. From and after the effective
date of the Omnibus Amendment, the term “Licensed Technology” includes MTA Technology relevant to Heterodimerizers in the Licensed Field. 

(c) Section 2.1.4 of the License Agreement is hereby deleted and replaced with the following:  

Right to Sublicense and Subcontract. Bellicum shall have the right to grant sublicenses to any Affiliate and/or Sublicensee to all or any
portion of its rights under the license granted pursuant to Section 2.1.1; provided, however, that (a) such sublicense under the license granted pursuant to Section 2.1.1 shall be granted in connection with a license to all Patent
Rights and Technology Controlled by Bellicum, which are necessary or useful in the manufacture, use or sale of the Licensed Product(s) covered by the sublicense, (b) no sublicense may include a right to further sublicense any [***] IP unless
[***] has provided prior written consent to Bellicum and ARIAD allowing such further sublicense (and, if requested by Bellicum, ARIAD will assist Bellicum in obtaining such consent from [***]), and all such sublicenses of [***] IP shall be subject
and subordinate to, and consistent with, the terms and conditions of the [***] Agreement with respect to sublicenses of [***] IP, (c) ARIAD shall be notified of the grant of a sublicense to any and all potential sublicenses, (d) any and
all sublicenses shall be subject to, and consistent with, the terms and conditions of this Agreement, (e) upon termination of this Agreement, any such sublicense shall be considered a fully-paid, direct license from ARIAD, as provided in
Section 9.3 as amended hereby, and (f) Bellicum shall provide ARIAD with a copy of each such sublicense agreement (from which Bellicum may redact confidential terms that are not necessary to disclose to ARIAD for purposes of confirming
compliance with this Agreement and the [***] Agreement) within thirty (30) days of execution. In addition, Bellicum shall have the right to subcontract with any 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 5 

 CONFIDENTIAL 

 
 
Third Party, including [***], to have such Third Party perform work on Bellicum’s behalf pursuant to the license granted pursuant to Section 2.1.1 on terms which are subject to, and
consistent with, the terms and conditions of this Agreement. ARIAD acknowledges and agrees that, after the effective date of the Omnibus Amendment, Bellicum has no obligation to ARIAD to collect payments from its current or future sublicensees in
respect of any sublicense of the rights granted to Bellicum under this Agreement. 
 (d) Section 2.1.2 is hereby deleted from
the License Agreement and replaced with the words “This section intentionally omitted.” All other provisions of Section 2.1 of the License Agreement (Sections 2.1.3 and 2.1.5 through 2.1.9) remain unchanged and in full force and
effect. 
 (e) Bellicum’s obligation to develop and commercialize certain Licensed Products in the Licensed Field, as set
forth in Section 3.2 of the License Agreement, will continue until ARIAD’s parallel obligation to [***] terminates upon the expiry of the patents as set forth in the agreement between ARIAD and [***]. Upon the date of termination of such
parallel obligation of ARIAD, all of Bellicum’s obligations under Section 3.2 of the License Agreement are automatically terminated. 

(f) Section 3.4 of the License Agreement is amended by adding the following sentence at the end thereof: “For clarity, ARIAD
retains the right to manufacture or have manufactured any Dimerizer other than [***] for use outside the Licensed Field, and to grant licenses to Third Parties to do so, subject to ARIAD’s compliance with Section 2.2.1(a).” 

(g) All other provisions of Article 3 of the License Agreement (Sections 3.1, 3.3 and 3.5) remain unchanged and in full force and
effect. 
 (h) With the exception of Section 4.1.4 (which continues in full force and effect), Sections 4.1 through 4.3
of the License Agreement have no further force and effect and are deleted from the License Agreement. Each such deleted section is hereby replaced with the words: “This section intentionally omitted.” 

(i) Under Section 6.1 of the License Agreement, ARIAD will continue to have the sole right, but not the obligation, to prepare,
file, prosecute, obtain and maintain the Licensed Patent Rights, other than the Licensed Patent Rights covering the [***]-ARIAD MTA Technologies, which are currently being prepared, filed, prosecuted, obtained and maintained by Bellicum pursuant to
ARIAD’s delegation of such responsibility to Bellicum. ARIAD will give good faith consideration to Bellicum’s requests and input regarding such activities in connection with the Licensed Patent Rights, and will not discontinue such
activities or materially diminish the scope of claims within any Licensed Patent Rights without prior written notice to Bellicum and good faith consideration of Bellicum’s interests and comments. If ARIAD wishes to discontinue payments for
maintenance of any patent within the Licensed Patent Rights, ARIAD hereby grants to Bellicum the right to make such maintenance payments for such patent.  

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 6 

 CONFIDENTIAL 

 
 
Notwithstanding anything to the contrary in Section 6.1 of the License Agreement, the following will apply from and after the Effective Date: In relation to Section 6.1 of the License
Agreement, ARIAD will continue to have the first right to enforce any Licensed Patent Rights, provided, however that (1) if ARIAD elects not to enforce any of the Licensed Patent Rights owned by ARIAD against alleged infringement by the
manufacture, use, sale or import by a Third Party(ies) (as defined in the License Agreement) of a product within the definition of “Licensed Product” in the Licensed Field, Bellicum may do so at its sole expense without any further consent
required from ARIAD; and (2) if ARIAD elects not to enforce any of the Licensed Patent Rights licensed by ARIAD from a Third Party(ies) against alleged infringement by the manufacture, use, sale or import by a Third Party(ies) of a product
within the definition of “Licensed Product” in the Licensed Field, then to the full extent that ARIAD may do so under its license agreement with such Third Party(ies), but subject to any right of such Third Party(ies) to enforce such
Licensed Patent Rights, ARIAD will delegate to Bellicum the right to enforce such Licensed Patent Rights at Bellicum’s sole expense; provided that, if such consent is required under any license agreement from a Third Party(ies), ARIAD will use
good faith efforts to obtain consent to delegate such enforcement right to Bellicum; and further provided that, if the Third Party licensor agrees that ARIAD may enforce such Licensed Patent Rights on behalf of Bellicum, but will not consent to
delegation of such enforcement right to Bellicum, then ARIAD will exercise its enforcement right on behalf of Bellicum, at Bellicum’s direction and expense. In addition, any filing, prosecution and/or maintenance rights, and any enforcement
rights, that ARIAD possesses under an Academic MTA shall be treated in the same manner as Licensed Patent Rights described in Section 6.1 of the License Agreement (as modified by this Section 3.1(i)). 

(j) Section 9.3 of the License Agreement is hereby amended by deleting clause (a) (ii) thereof and by deleting from
clause (b) the words “with royalties to be paid to ARIAD on all Net Sales of such Licensed Products as provided for in this Agreement.” 

(k) ARIAD will not sell, transfer, pledge or otherwise dispose of any shares of Bellicum Common Stock, unless (i) Bellicum has
completed a registered public offering of its Common Stock (an “IPO”) at any time and has not made the Second Payment by October 31, 2015 (including applicable interest commencing July 1, 2015 as set forth in
Section 3.2(b) of this Agreement); or (ii) each of the License Agreement and this Agreement has been terminated. 
 (l)
ARIAD will not modify the [***] Agreement or the [***] Agreement in any manner, and will not take or fail to take any actions that would diminish Bellicum’s rights or increase Bellicum’s obligations under those agreements.
Notwithstanding anything to the contrary in the License Agreement, ARIAD will be solely responsible for paying, and shall pay, any and all royalties, milestone payments and other payments owed under the [***] Agreement as a result of Net Sales or
milestone achievements by Bellicum, its Affiliates or Sublicensees. If the [***] Agreement is terminated (as described in Section 2.1.9 of the License Agreement), ARIAD will remain responsible for making any payments to [***] that are owed as a
result of Bellicum’s activities as a direct licensee of [***].  

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 7 

 CONFIDENTIAL 

 
 (m) Bellicum recognizes that ARIAD has executed numerous
Academic MTAs, pursuant to many of which ARIAD has obtained certain non-exclusive rights which may be useful to Bellicum in the practice of the licenses granted to Bellicum under the License Agreement (as amended by this Agreement). ARIAD has
provided to Bellicum before the Effective Date a listing of such Academic MTAs which ARIAD believes (but does not represent) is complete. To the extent necessary and permitted by any Academic MTA, ARIAD consents to Bellicum contacting the researcher
or his or her institution or entity under such Academic MTA to discuss or seek rights to the intellectual property rights resulting from the research conducted thereunder. Subject to any confidentiality obligation under any Academic MTA, ARIAD will
notify Bellicum in writing of the existence of patents and patent applications relevant to the research, development, testing, manufacture, use, sale or import of Licensed Products in the Licensed Field, and disclosed to ARIAD in connection with
such Academic MTAs. If ARIAD has a right to negotiate for any option or license rights to such patents and patent applications, then at Bellicum’s written request, ARIAD will reasonably cooperate with Bellicum to seek to obtain a right for
Bellicum to negotiate for such option or license rights to such patents and patent applications; provided that if ARIAD has a right to convey such option or license rights to another party, but is unable to obtain such negotiation right for Bellicum
after good faith efforts, then if the other party to the Academic MTA agrees that ARIAD may negotiate such option of license rights on behalf of Bellicum, but will not consent to delegation of such negotiation right to Bellicum, ARIAD will cooperate
with Bellicum in negotiating such option or license rights on behalf of Bellicum, and convey to Bellicum the negotiated rights, all at Bellicum’s sole expense. If Bellicum believes that a researcher, or his or her institution or entity, is not
complying with his/her Academic MTA, ARIAD and Bellicum will cooperate to ensure that such researcher is in compliance.  
 3.2
Upon Second Payment. From and after the date of ARIAD’s receipt of the Second Payment (together with any applicable interest payable pursuant to subsection (b) below) (“Second Payment Date”): 

(a) ARIAD will surrender to Bellicum all shares of Bellicum Common Stock held by ARIAD as of the Second Payment Date, provided that the
Second Payment Date is no later than December 31, 2015, and concurrently with such surrender of shares, each of the SPA and IRA will terminate and have no further force or effect (unless the SPA and/or the IRA has/have previously terminated in
accordance with its/their respective terms). 
 (b) If the Second Payment is not delivered by Bellicum on or before
June 30, 2015, then, from July 1, 2015 until such time as the Second Payment, plus interest from July 1, 2015 (at the rate of ten percent (10%) per annum or the maximum rate allowed by applicable law, if lower), is paid in full:
(i) ARIAD will not surrender the Bellicum Common Stock held by ARIAD; (ii) each of the SPA and IRA will continue in full force and effect, unless terminated upon an IPO in accordance with their respective terms; (iii) under
Section 2.1.4 of the License Agreement, any right of Bellicum to grant sublicenses without ARIAD’s consent will be suspended until the Second Payment is delivered; (iv) Bellicum shall pay ARIAD, from an 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 8 

 CONFIDENTIAL 

 
 
escrow account held by an independent third party to be established at the time of the first receipt of Cash Consideration (defined below) to provide funds for such payment, (A) on
July 1, 2015, fifty percent (50%) of any cash consideration received by Bellicum under sublicense agreements and directly related contemporaneous agreements executed by Bellicum with such sublicensees (“Cash
Consideration”) subsequent to August 22, 2014 and prior to July 1, 2015; provided that the following are expressly excluded from such Cash Consideration described in this Section 3.2(b) and in Section 3.3(b) below:
amounts received by Bellicum (1) in arrears and based on reported expenditures of time and materials for the performance of bona fide product development work or research work, (2) for equity (including, convertible equity, such as
warrants and convertible debt) at fair market value, and (3) in arrears and based on reported expenditures for patent expenses incurred by Bellicum; and (B) one hundred percent (100%) of any milestone payments that would have been
owed by Bellicum to ARIAD under the License Agreement as it existed prior to the Effective Date, if the corresponding milestone event is achieved subsequent to the Effective Date of this Agreement and prior to the Second Payment Date. 

(c) For avoidance of doubt, Bellicum’s failure to deliver the Second Payment on or before June 30, 2015 does not give ARIAD
the right to terminate the License Agreement in response to such failure. 
 (d) If the Second Payment is not delivered by
Bellicum on or before June 30, 2016, ARIAD will have the right, in its sole discretion, to terminate the License Agreement in its entirety upon delivery to Bellicum of written notice of termination that makes reference to this
Section 3.2(d). In the event of such termination, this Agreement shall be terminated automatically. For clarity, termination of this Agreement pursuant to this Section 3.2(d) shall not terminate the Note, which shall continue in full force
and effect. 
 3.3 Upon Third Payment. From and after the date of ARIAD’s receipt of the Third Payment (together with any
applicable interest payable pursuant to subsection (b) below) (“Third Payment Date”): 
 (a) If the
Third Payment is delivered by Bellicum on or before June 30, 2016, the defined term Licensed Product will be further amended and expanded in scope to the extent permitted by ARIAD’s pre-existing obligations and agreements, as follows:

 “Licensed Product” shall mean any prophylactic or therapeutic product the manufacture, sale, import, administration,
activation or other use of which is covered by a claim of any Licensed Patent Rights or by Licensed Technology (including, without limitation, Patent Rights licensed or assigned to Bellicum that cover any of the [***]-ARIAD MTA Technologies) and
that (a) contains proteins or genes encoding proteins, the interaction or proximity of which proteins is induced by either a Homodimerizer or a Heterodimerizer; (b) is a Homodimerizer or Heterodimerizer for use with a product described in
clause (a); or (c) is a  

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 9 

 CONFIDENTIAL 

 
 
treatment regimen or process utilizing any product described in clause (a) or (b). For clarity, this definition of Licensed Product expressly includes those products that are within the
definition of Licensed Product as of the effective date of the Omnibus Amendment. 
 (b) If the Third Payment is not delivered by
Bellicum on or before June 30, 2016, then from July 1, 2016 until such time as the Third Payment, plus interest from July 1, 2016 (at the rate of ten percent (10%) per annum or the maximum rate allowed by applicable law, if
lower), is paid in full: (i) under Section 2.1.4 of the License Agreement, any right of Bellicum to grant sublicenses without ARIAD’s consent will be suspended until the Third Payment is delivered; (ii) Bellicum shall pay ARIAD,
from an escrow account to be established to provide funds for such payment, (A) on July 1, 2016, fifty percent (50%) of any Cash Consideration received by Bellicum subsequent to the date of the Second Payment and prior to July 1,
2016 (excluding amounts paid to ARIAD pursuant to Section 3.2(b)(iv)(A) above), and (B) one hundred percent (100%) of any milestone payments that would have been owed by Bellicum to ARIAD under the License Agreement as it existed
prior to the effective date of the Omnibus Amendment, if the corresponding milestone event is achieved subsequent to the Second Payment Date and prior to the Third Payment Date (excluding amounts paid to ARIAD pursuant to Section 3.2(b)(iv)(B)
above). 
 (c) During any period in which the Second Payment or the Third Payment, as applicable, remains unpaid past its due
date, fifty percent (50%) of any funds raised by Bellicum in any private equity or debt financing for capital raising purposes (i.e., not including bank line-of-credit or equipment financings) (“Raised Capital”) will be applied
against such past due, unpaid amount. If all of the Second Payment and Third Payment have not been delivered by Bellicum on or before June 30, 2017, ARIAD will have the right, in its sole discretion, to terminate the License Agreement, upon
delivery to Bellicum of written notice of termination that makes reference to this Section 3.3(c). In the event of such termination, this Agreement shall be terminated automatically. 

(d) Bellicum shall maintain and keep, until the Third Payment has been delivered to ARIAD, complete and accurate records of
(i) all Cash Consideration received by Bellicum as set forth in Sections 3.2(b)(iv)(A) and 3.3(b)(ii)(A), (ii) all Raised Capital as set forth in Section 3.3(c) and (iii) achievement of milestone events as set forth in Sections
3.2(b)(iv)(B) and 3.3(b)(ii)(B). Subject to the other terms of this Section 3.3(d), at the request of ARIAD, which request shall not be made more than once per calendar year during the Term, then upon at least thirty (30) days’ prior
written notice from ARIAD, and at the expense of ARIAD (except as otherwise provided herein), Bellicum shall permit an independent certified public accountant reasonably selected by ARIAD and reasonably acceptable to Bellicum to inspect (during
regular business hours) the relevant records required to be maintained by Bellicum under this Section 3.3(d) (provided no records may be reviewed more than once under this Section 3.3(d)). Results of such inspection shall be binding on
both Parties absent manifest error. ARIAD shall treat the results of any such accountant’s review of records under this  

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 10 

 CONFIDENTIAL 

 
 
Section 3.3(d) as Confidential Information of Bellicum subject to the terms of Section 5.1 of the License Agreement. If any such inspection reveals a deficiency in the calculation of
amounts deposited in the escrow account and/or payment by Bellicum required by Section 3.2(b)(iv) or 3.3(b)(ii), then Bellicum shall promptly add such deficiency to the escrow account or pay ARIAD the amount remaining to be paid. 

 

	4.	BELLICUM COMPANY SALE AND PUBLIC OFFERINGS. 

4.1 Payment Due Date Modification in the Event of Company Sale or Certain Registered Public Offerings. In the event of a Company Sale
(as defined in the SPA) of Bellicum, any remaining balance of the Second Payment and the Third Payment that has not been paid shall become due and payable at the closing of the Company Sale. In the event Bellicum raises (a) Seventy-Five Million
US dollars ($75,000,000) or more in one or more registered public offerings (a “Public Offering”) on or before March 31, 2015, or (b) One Hundred Million US dollars ($100,000,000) or more in one or more Public Offerings
subsequent to March 31, 2015, then, the Third Payment will become due and payable on the date that is the earlier of (x) nine (9) months after the closing of the Public Offering that brings the aggregate proceeds received by Bellicum
(before expenses, discounts and commissions and other deductions from the gross amount of the Public Offering (“Gross Proceeds”)) to at least $75 million or $100 million, as applicable; or (y) in the event of a Public Offering
resulting in aggregate Gross Proceeds received by Bellicum of at least $100 Million, December 31, 2015. Notwithstanding the foregoing, if Bellicum completes an IPO and a secondary Public Offering that alone or together raise aggregate Gross
Proceeds of at least One Hundred Twenty-Five Million US dollars ($125,000,000), the Third Payment shall become due and payable within five (5) days of the closing of the IPO or secondary Public Offering that results in aggregate Gross Proceeds
received by Bellicum of at least One Hundred Twenty-Five Million US dollars ($125,000,000). In no event shall the Third Payment be due later than June 30, 2016. 
  

	5.	CONSTRUCTION OF AGREEMENT. 

 5.1 Entire
Agreement. (a) This Agreement shall be effective for all purposes as of the Effective Date. To the extent that there are any inconsistencies between the express provisions of this Agreement and any of the Current Agreements, the terms of
this Agreement shall supersede those set forth in the Current Agreements. Except as expressly modified by this Agreement, each of the Current Agreements shall remain in full force and effect in accordance with its terms. As of the Effective Date,
the term “Agreement” as used in the Current Agreements shall mean the Current Agreements as amended by this Agreement. (b) This Agreement, together with the Current Agreements, as amended hereby, constitutes the entire agreement
between the Parties with respect to the subject matter of the Current Agreements and this Agreement. No modification shall be effective unless in writing with specific reference to this Agreement and signed by the Parties. (c) The terms of this
Agreement are hereby deemed confidential information of each Party, and this confidential information shall be treated in the same manner under this Agreement as “Confidential Information” is treated under the License 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 11 

 CONFIDENTIAL 

 
 
Agreement; provided, however, that subject to the following sentence, the Parties intend to issue a joint press release upon full execution of this Agreement, and thereafter either Party may
issue a press release upon delivery of the Second Payment and the Third Payment, and in the event of termination of this Agreement. Each Party shall provide any proposed press release in connection with this Agreement, the Second Payment or the
Third Payment to the other Party at least five (5) days prior to issuing such proposed press release, and shall give good faith consideration to comments from the other Party. 

5.2 Disputes. In the event of the occurrence of a dispute as to either Party’s rights and/or obligations hereunder, the resolution
of the dispute will be governed by Article 10 of the License Agreement.  
 5.3 Governing Law. This Agreement will be
construed, interpreted and applied in accordance with the laws of the State of New York (excluding its body of law controlling conflicts of law). 

5.4 Counterparts. This Agreement may be executed in any number of counterparts by original, facsimile or PDF signature, each of which
shall be deemed an original, and all of which together shall constitute one and the same instrument, binding on the Parties notwithstanding that each of the Parties may have signed different counterparts. 

5.5 Waiver. The terms or conditions of this Agreement may be waived only by a written instrument executed by Bellicum and ARIAD. The
failure of either Party at any time or times to require performance of any provision hereof shall in no manner affect its rights at a later time to enforce the same. No waiver by either Party of any condition or term shall be deemed as a continuing
waiver of such condition or term or of another condition or term. 
 5.6 Assignment. Neither this Agreement nor any right or
obligation hereunder may be assigned, delegated or otherwise transferred, in whole or part, by either Party without the prior written consent of the other Party; provided, however, that either Party may, without the written consent of the other,
assign this Agreement and its rights and delegate its obligations to its Affiliates or in connection with the transfer or sale of all or substantially all of such Party’s assets or business related to this Agreement, or in the event of its
merger, consolidation, change in control or similar transaction. Any permitted assignee shall assume all obligations of its assignor under this Agreement. Any purported assignment in violation of this Section 5.5 shall be void. The terms and
conditions of this Agreement shall be binding upon and inure to the benefit of the permitted successors and assigns of the Parties. 
  

	6.	HEDGING TRANSACTIONS. 

 6.1 Until such time as all
payments due hereunder or under the Note have been made by Bellicum to ARIAD, Bellicum will not engage in any Hedging Transaction with Comerica Bank, any affiliate of Comerica Bank, or any successor in interest to the rights of Comerica Bank under
the Subordination Agreement dated October 3, 2014 by and among 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 12 

 CONFIDENTIAL 

 
 
Comerica Bank, ARIAD and Bellicum. As used herein, “Hedging Transaction” means any interest rate swap transaction, basis swap transaction, forward rate transaction, equity transaction,
equity index transaction, foreign exchange transaction, cap transaction, floor transaction (including any option with respect to any of these transactions and any combination of any of the foregoing). 

[Signature page follows.] 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 13 

 CONFIDENTIAL EXECUTION VERSION 

IN WITNESS WHEREOF, the Parties hereto have caused their duly authorized representatives to
execute this Omnibus Amendment Agreement as of the Effective Date. 
  

									
	ARIAD PHARMACEUTICALS, INC.				BELLICUM PHARMACEUTICALS, INC.
			
	 /s/ Hugh M. Cole
				 /s/ Thomas J. Farrell

			(signature)						(signature)
	By:		 Hugh M. Cole
				By:		 Thomas J. Farrell

			(print or type name)						(print or type name)
	Title:		 Chief Business Officer
				Title:		 Chief Executive Officer

					
	Date:		 October 3, 2014
				Date:		 October 3, 2014

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

 CONFIDENTIAL EXECUTION VERSION 

Schedule A1 
 Homodimerizer
Patent Rights 
 Technologies Other Than [***]-ARIAD MTA Technologies 
  

							
	 Title
	  	 Country
	  	 Serial No.
	  	 Patent No.

	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	
	  	[***]	  	[***]	  	

 ] 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

 CONFIDENTIAL 

 
 Schedule A2 

Heterodimerizer Patent Rights 
 Technologies
Other Than [***]-ARIAD MTA Technologies 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 2 

 CONFIDENTIAL 

 

									
	 Title
	  	 Country
	  	 Serial No.
	  	 Patent No.
	  	 Issued

	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]
	  	[***]	  	[***]	  	[***]	  	[***]

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 3 

 CONFIDENTIAL 

 

									
			[***]		[***]		[***]		[***]
		[***]		[***]		[***]		[***]
		[***]		[***]		[***]		[***]
		[***]		[***]		[***]		[***]
		[***]		[***]		[***]		[***]
		[***]		[***]		[***]		[***]
	[***]		[***]		[***]		[***]		[***]

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 4 

 CONFIDENTIAL EXECUTION VERSION 

Schedule A3 
 [***]-ARIAD
MTA Technologies 
  

									
	 Country
	  	 Publication
No.
	  	 Serial No.
	  	 Title
	  	 Patent
No.

	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  		  	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]	  	[***]	  	
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  		  	[***]	  	[***]	  	[***]

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

 CONFIDENTIAL 

Exhibit B 
 Section 2.2
Material Breaches 
 Section 2.1.1 — any act or omission by ARIAD that is inconsistent with, or that materially adversely affects, the rights and
licenses granted to Bellicum as set forth in Section 2.1.1; 
 Section 2.1.3(a) – any act by ARIAD that is inconsistent with the prohibitions
imposed on ARIAD pursuant to Section 2.1.3(a), including, but not limited to, any such act that materially adversely changes any such prohibition, or that to any extent releases ARIAD from any such prohibition; 

Section 2.1.4 — any act or omission by ARIAD that is inconsistent with, or that materially adversely affects, Bellicum’s right to grant
sublicenses and to subcontract with Third Parties, as set forth in Section 2.1.4, including, but not limited to, any act or omission whereby ARIAD fails to take steps to assist Bellicum in obtaining consent from [***], as set forth in clause
(b) of Section 2.1.4; 
 Section 2.1.5 – any willful or intentional material breach of ARIAD’s obligation to disclose all Licensed
Patent Rights and Licensed Technology as set forth in Section 2.1.5; 
 Section 2.1.6 – any act or omission by ARIAD that materially
adversely affects Bellicum’s right to receive, or Bellicum’s receipt of, ARIAD Regulatory Information as set forth in Section 2.1.6; 

Section 2.2.1(a) – any act by ARIAD that constitutes a material breach of Section 2.2.1(a) solely due to (i) the practice by ARIAD of any
Bellicum Patent Rights, Bellicum Technology or Bellicum’s interest in any Improvements, or (ii) the grant by ARIAD to a Third Party of a sublicense to practice Bellicum Patent Rights, Bellicum Technology and or Bellicum’s interest in
any Improvements, in either case (i) or (ii) to develop, make, have made, use, have used, sell, offer for sale, have sold, import, have imported, export or have exported ARIAD Products in the Licensed Field; 

Section 4.1.4 – any willful or intentional material breach of ARIAD’s royalty payment obligation set forth in the first sentence of
Section 4.1.4; 
 Sections 5.1, 5.2 and 5.3 – any material breach of ARIAD’s confidentiality obligations owed to Bellicum that materially
adversely affects the Licensed Patent Rights licensed to Bellicum by ARIAD; and 
 Section 6 — any act or omission by ARIAD that constitutes a
material breach of ARIAD’s obligations under Section 6.1, and where such material breach materially adversely affects the Licensed Patent Rights licensed to Bellicum by ARIAD 

  
 Portions of this Exhibit, indicated
by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. 

  
 2EX-10.16

 Exhibit 10.16 

Execution Copy 

Executive Employment Agreement 

ARIAD Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, and Thomas J. DesRosier (the “Employee”) enter into
the following Executive Employment Agreement as of the 20th day of January, 2015 (hereafter, the “Agreement”). 
 WHEREAS, the
Company wishes to offer the Employee employment according to the following terms and conditions; 
 WHEREAS, the Employee wishes to accept
employment with the Company on such terms; 
 WHEREAS, the parties mutually intend that this Agreement shall be the sole agreement between
them concerning the Company’s employment of the Employee and the terms and conditions of such employment; 
 NOW, THEREFORE, the
Company and the Employee agree as follows: 
 1. Employment, Duties and Acceptance. 

1.1 The Company hereby employs the Employee, for the Term (as hereinafter defined), to render full-time services to the Company, and to
perform such duties, as the Chief Executive Officer of the Company shall reasonably direct Employee to perform. The Employee’s initial title shall be Executive Vice President, Chief Legal and Administrative Officer and Secretary, and he shall
report to the Company’s Chief Executive Officer, unless and until the Chief Executive Officer shall change such title, in his sole discretion. 

1.2 The Employee hereby accepts such employment and agrees to render the services described above. 

 Execution Copy 

 

 1.3 The principal place of employment of the Employee hereunder shall be in the greater
Boston, Massachusetts area, or other locations reasonably acceptable to the Employee. The Employee acknowledges that, for limited periods of time, Employee may be required to provide services to the Company outside of the Boston, Massachusetts area.

 1.4 Notwithstanding anything to the contrary herein, although the Employee shall provide services as a full-time employee, it is
understood that the Employee may (a) have an academic appointment and (b) participate in professional activities (collectively, “Permitted Activities”); provided, however, that such Permitted Activities do not
interfere with the Employee’s duties to the Company. 
 1.5 The Employee represents and affirms that, as of the Effective Date,
Employee does not have any other contractual obligations to any other person or entity that would prohibit or limit Employee’s employment with the Company or that would conflict with the terms of this Agreement, except for the duty not to use
or disclose another entity’s confidential information without authorization. Employee further acknowledges that the Company instructs Employee not to bring to ARIAD, use or disclose in the course of Employee’s employment any confidential
information belonging to another person or entity, without that person or entity’s express authorization. 
 2. Term of
Employment. 
 The term of the Employee’s employment under this Agreement (the “Term”) shall commence on
January 26, 2015 (the “Effective Date”), as mutually agreed upon by the parties, and shall end on December 31, 2017, unless sooner terminated pursuant to Section 4 or 5 of this Agreement; provided, however,
that this Agreement shall automatically be renewed for 

  
 2 

 Execution Copy 

 

 
successive one-year terms (the Term and, if the period of employment is so renewed, such additional period(s) of employment are collectively referred to herein as the “Term”), unless
one or more of the parties gives written notice to the other at least ninety (90) days prior to the end of the applicable Term that it does not intend to renew the Term (a “Notice of Non-Renewal”), in which case the employment will
end and the Term shall expire, without further action by either party, at the end of the day that is immediately before the next anniversary of the Effective Date. 

3. Compensation. 
 3.1
As full compensation for all services to be rendered pursuant to this Agreement, the Company agrees to pay the Employee, during the Term, a base salary at the fixed rate of $485,000 per annum, and increased each year, by amounts, if any, to be
determined by the Compensation Committee of the Board of Directors of the Company (the “Board”), in its sole discretion, payable in equal biweekly installments, less such deductions or amounts to be withheld as shall be required by
applicable law and regulations. 
 3.2 Each year, Employee shall be eligible to receive a discretionary bonus. The target for such
discretionary bonus shall be fifty (50) percent of Employee’s base salary, but the Company may elect to pay a greater or lesser bonus, in its sole discretion, which shall be determined annually by the Board. Factors that may be considered
by the Board in determining bonus eligibility and the size of a bonus awarded, if any, include the Employee’s level of performance, the Company’s achievement of its business goals, and special contributions that the Employee may have made
during the year under consideration. The bonus, if any, may be paid in the form of stock options, restricted stock, restricted stock units, performance 

  
 3 

 Execution Copy 

 

 
shares, deferred compensation or cash, as determined by the Board. In the event of any conflict between any equity-based or other compensation plan documents and this Agreement, the terms of this
Agreement shall control. 
 3.3 Subject to the approval of the Compensation Committee of the Board, the Company shall grant the Employee an
option to purchase 130,000 shares of the Company’s Common Stock at the fair market value on the date of approval by the Compensation Committee. The Employee agrees that all such options shall be subject to a four-year vesting schedule, vesting
in equal increments of twenty-five (25) percent on each anniversary of their issuance. Any unvested options shall be forfeited to the Company in the event (i) the Company terminates this Agreement for Cause pursuant to Section 4(c)
herein, or (ii) either party elects not to renew this Agreement pursuant to Section 2 herein. 
 3.4 Subject to the approval of
the Compensation Committee of the Board, the Company shall grant the Employee 110,000 ARIAD restricted stock units on the date of the Board’s approval of the grant. The Employee agrees that all such restricted stock units shall be subject to a
period of restriction as to transfer and to repurchase by the Company with respect to fifty (50) percent of such grant until the first anniversary of the date of grant and the remaining fifty (50) percent of such grant until the second
anniversary of the date of grant, and the underlying shares of the Company’s Common Stock shall be issued upon the lapsing of such periods of 

  
 4 

 Execution Copy 

 

 
restriction. Unvested restricted stock units shall be forfeited to the Company in the event (i) the Company terminates this Agreement for Cause pursuant to Section 4(c) herein, or
(ii) either party elects not to renew this Agreement pursuant to Section 2 herein. 
 3.5 The Employee shall be eligible under
any incentive plan, stock-based compensation plan, bonus, deferred or extra compensation plan, pension, group health, disability, long-term care, and life insurance or other so-called “fringe” benefits, which the Company provides for its
executives at the comparable level. All stock awards, stock options, restricted stock, restricted stock units, performance shares or bonuses in the form of deferred compensation granted to the Employee by the Company prior to the Effective Date or
in the future shall be subject to vesting schedules, which shall be determined by the Compensation Committee of the Board. All stock awards, stock options, restricted stock, restricted stock units, or performance shares granted to the Employee shall
also be subject to the terms of the Company’s equity-based or other compensation plan documents under which such grants were made and any certificates issued to the Employee in association with such grants. Any unvested stock awards, stock
options, restricted stock, restricted stock units, performance shares or unvested portions of past bonuses in the form of deferred compensation shall be forfeited to the Company in the event (a) this Agreement is terminated by the Company for
Cause pursuant to Section 4(c) herein, or (b) either party elects not to renew this Agreement pursuant to Section 2 herein. This 

  
 5 

 Execution Copy 

 

 
forfeiture provision shall apply to stock awards, stock options, restricted stock, restricted stock units or performance shares and bonuses in the form of deferred compensation that have been
awarded prior to or concurrent with the Effective Date of this Agreement, as well as those that may be awarded in the future. 
 3.6 To
facilitate the Employee’s transition to the Company, the Company shall provide the Employee with a one-time transition advance (the “Advance”) in the gross amount of $75,000, as follows: fifty (50) percent of which shall be
payable by the Company within thirty (30) days of the Effective Date and the remaining fifty (50) percent at six (6) months after the Effective Date. Notwithstanding the foregoing, (i) if the Employee terminates his employment or
this Agreement prior to the second anniversary of the Effective Date, except as provided pursuant to Section 5.1(a) herein, or (ii) the Company terminates this Agreement for Cause at any time pursuant to Section 4(c) herein, then the
Employee shall be obligated to repay the Advance within thirty (30) days of such termination. If the Employee remains employed with the Company in good standing as of the second anniversary of the Effective Date, then the Advance shall no
longer be subject to repayment by the Employee. The Employee authorizes the Company to withhold from final wages, expense reimbursements, or other forms of compensation due to him at the time of separation the Advance that he is required to repay.

  
 6 

 Execution Copy 

 

 4. Termination by the Company. 

The Company may terminate this Agreement, if any one or more of the following shall occur: 

(a) The Employee shall die during the Term; provided, however, the Employee’s legal representatives shall be entitled to
receive the compensation provided for hereunder to the last day of the month in which Employee’s death occurs. 
 (b) The Employee
shall become physically or mentally disabled, whether totally or partially, so that he is unable substantially to perform his services hereunder for (i) a period of one-hundred eighty (180) consecutive days, or (ii) for shorter
periods aggregating one-hundred eighty (180) days during any twelve (12) month period. 
 (c) The Employee acts, or fails to act,
in a manner that provides Cause for termination, as determined in the sole discretion of the Chief Executive Officer of the Company. For purposes of this Agreement, the term “Cause” means (i) the failure by the Employee to perform any
of Employee’s material duties hereunder, (ii) the conviction of the Employee of any felony, (iii) the commission of any crime relating to Employee’s employment with the Company, (iv) violation of any federal, state or local
law, or administrative regulation related to the business of the Company, (v) conduct that could result in publicity reflecting unfavorably on the Company, (vi) unprofessional conduct inconsistent with the Employee’s position in the
Company, (vii) failure to comply with the written policies of the Company, or (viii) a material breach of the terms of this Agreement by the Employee (including, without limitation, actions taken by the Employee which create a conflict of
interest for Employee between the Company or any of its Affiliates and a competitor). If the conduct constituting Cause hereunder is susceptible to cure, the Company shall provide the Employee written notice of

  
 7 

 Execution Copy 

 

 
termination pursuant to this Section 4, and Employee shall have thirty (30) days to cure or remedy such failure or breach, in which case this Agreement shall not be terminated. If the
conduct is not susceptible to cure as determined by the Chief Executive Officer of the Company in his or her sole discretion, this Agreement shall terminate upon written notice by the Company. 

(d) The Company elects to terminate the Employee’s employment and this Agreement in circumstances not constituting Cause (as defined
above), in which case the Company is not required to provide advance notice, but the Employee may be eligible for salary continuation payments and other benefits under Section 6.1 or Section 6.2 below. 

5. Termination by the Employee. 

5.1 The Employee may terminate this Agreement, within ninety (90) days of the initial occurrence of any one or more of the following:

 (a) a material breach of the terms of this Agreement by the Company and such breach continues for thirty (30) days after the
Employee gives the Company written notice of such breach and an opportunity to cure it; 
 (b) the Company shall make a general assignment
for benefit of creditors; or any proceeding shall be instituted by the Company seeking to adjudicate it as bankrupt or insolvent, or seeking liquidation, winding up, reorganization, arrangement, adjustment, protection, relief, or composition of it
or its debts under law relating to bankruptcy, insolvency or reorganization or relief of debtors, or seeking entry of an order for relief or the appointment of a receiver, trustee, or other similar official for

  
 8 

 Execution Copy 

 

 
it or for any substantial part of its property or the Company shall take any corporate action to authorize any of the actions set forth above in this subsection 5(b); 

(c) an involuntary petition shall be filed or an action or proceeding otherwise commenced against the Company seeking reorganization,
arrangement or readjustment of the Company’s debts or for any other relief under the Federal Bankruptcy Code, as amended, or under any other bankruptcy or insolvency act or law, state or federal, now or hereafter existing and remain undismissed
or unstayed for a period of thirty (30) days; 
 (d) a receiver, assignee, liquidator, trustee or similar officer for the Company or
for all or any part of its property shall be appointed involuntarily; or, 
 (e) a Change in Control as defined in Section 15. 

6. Severance. 
 6.1 If
(i) the Company terminates this Agreement during the Term without Cause or (ii) the Employee terminates this Agreement during the Term pursuant to Sections 5.1(a), (b), (c), or (d), then: (1) except in the case of death or disability,
the Company shall continue to pay Employee his then-current salary for the period of twelve (12) months following the effective date of such termination; (2) the unvested portions of all stock awards, stock options, restricted stock or
restricted stock units and bonuses in the form of deferred compensation that would have vested during the Term shall vest upon the effective date of such termination; and (3) the Company shall continue to provide Employee coverage under the
Company’s group health insurance plan at the Company’s expense for up to one year 

  
 9 

 Execution Copy 

 

 
following the effective date of such termination, provided Employee makes an effective COBRA election regarding group health insurance. Except as otherwise required under Section 14.2,
salary continuation payments referenced in Sections 6.1(i)(1) and 6.1(ii)(1) above shall begin on the first regular pay date following Employee’s separation from service. The Employee will not be eligible for any payments or benefits under this
Section 6.1 if Employee is eligible to receive payments and benefits under the following Section 6.2. 
 6.2 In the event of a
consummation of a Change in Control of the Company, and if, upon such occurrence or within the period of one (1) year following such occurrence (and within the then current Term), the Company terminates the Employee’s employment during the
Term without Cause or the Employee resigns during the Term for “Good Reason” (as defined herein) and the Employee executes a separation agreement and release of claims in the Company’s standard form, then, subject to compliance with
Section 10 below, (i) all stock awards, stock options, restricted stock, restricted stock units or performance shares granted to the Employee and past bonuses in the form of deferred compensation granted to the Employee shall immediately
vest and remain fully exercisable through their original term with all rights; (ii) the Company shall continue to pay the Employee his then-current base salary for twenty-four (24) months; and (iii) if the Employee makes an effective
COBRA election regarding group health insurance, then the Company shall continue to provide the Employee with coverage under the Company’s group health plan at the Company’s expense for a period of eighteen (18) months following
Employee’s separation from the Company. Except as otherwise required under Section 14.2, salary continuation payments referenced in Section 6.2(ii) above shall begin on the 

  
 10 

 Execution Copy 

 

 
first regular pay date following the effective date of the separation agreement between Employee and the Company. Finally, the payments and benefits described in this Section 6.2 shall not
be available if Employee’s employment terminates due to death or disability during the Term and within one-year period following a Change of Control. 

6.3 If Employee receives any form of compensation for Employee’s provision of services (whether as employee, consultant, contractor or
otherwise) during the severance period described in Section 6.1 above, such compensation shall be offset against the severance owed to Employee by the Company. More specifically, if the Employee’s compensation from post-separation services
is less than the severance owed by the Company, then the Company will pay the difference between the two amounts to the Employee. If the Employee’s compensation from post-separation services is equal to or greater than the severance owed by the
Company, then the Company’s obligation to pay severance to the Employee will end. Employee agrees to inform the Company immediately if Employee enters into any agreement to provide services to another person or entity in exchange for any form
of compensation during the severance period stated in Section 6.1 above. Finally, irrespective of Employee’s provision of post-separation services, the Company’s obligation to provide paid COBRA health insurance coverage will continue
for the stated period unless Employee materially breaches this Agreement or withdraws from the Company’s plan during the stated period. 

6.4 The Employee shall bear all expense of, and be solely responsible for, all federal, state, local or foreign taxes due with respect to any
payment received under the Agreement, including, without limitation, any excise tax imposed by Section 4999 of the Code (the “Excise Tax”); provided, however, 

  
 11 

 Execution Copy 

 

 
that any payment or benefit received or to be received by the Employee in connection with a Change in Control or the termination of employment (whether payable under the terms of the Agreement or
any other plan, arrangement or agreement with the Company or an affiliate (collectively, the “Payments”) that would constitute a “parachute payment” within the meaning of Section 280G of the Code, shall be reduced to the
extent necessary so that no portion thereof shall be subject to the Excise Tax but only if, by reason of such reduction, the net after-tax benefit received by the Employee shall exceed the net after-tax benefit that would be received by the Employee
if no such reduction was made. For purposes of this Section 6.4: 
 (a) The “net after-tax benefit” shall mean (i) the
Payments which the Employee receives or is then entitled to receive from the Company or its affiliates that would constitute “parachute payments” within the meaning of Section 280G of the Code, less (ii) the amount of all
federal, state and local income and employment taxes payable by the Employee with respect to the foregoing calculated at the highest marginal income tax rate for each year in which the foregoing shall be paid to the Employee (based on the rate in
effect for such year as set forth in the Code as in effect at the time of the first payment of the foregoing), less (iii) the amount of Excise Tax imposed with respect to the payments and benefits described in (i) above. 

(b) All determinations under this Section 6.4 will be made by an accounting firm or law firm that is selected for this purpose by the
Company’s Chief Executive Officer prior to the Change in Control (the “280G Firm”). All fees and expenses of the 280G Firm shall be borne by the Company. The Company will direct the 280G Firm to submit any determination it makes under
this Section 6.4 and detailed supporting calculations to both the Employee and the Company as soon as reasonably practicable. 

  
 12 

 Execution Copy 

 

 (c) If the 280G Firm determines that one or more reductions are required under
Section 6.4, the 280G Firm shall also determine which Payments shall be reduced (first from cash payments and then from non-cash benefits) to the extent necessary so that no portion thereof shall be subject to the excise tax imposed by
Section 4999 of the Code, and the Company shall pay such reduced amount to the Employee. The 280G Firm shall make reductions required under this Section 6.4 in a manner that maximizes the net after-tax amount payable to the Employee. 

(d) As a result of the uncertainty in the application of Section 280G at the time that the 280G Firm makes its determinations under this
Section 6.4, it is possible that amounts will have been paid or distributed to the Employee that should not have been paid or distributed (collectively, the “Overpayments”), or that additional amounts should be paid or distributed to
the Employee (collectively, the “Underpayments”). If the 280G Firm determines, based on either the assertion of a deficiency by the Internal Revenue Service against the Company or the Employee, which assertion the 280G Firm believes has a
high probability of success or controlling precedent or substantial authority, that an Overpayment has been made, the Employee must repay to the Company, without interest; provided, however, that no loan will be deemed to have been made and no
amount will be payable by the Employee to the Company unless, and then only to the extent that, the deemed loan and payment would either reduce the amount on which the Employee is subject to tax under Section 4999 of the Code or generate a
refund of tax imposed under Section 4999 of the Code. If the 280G determines, based upon controlling precedent or substantial authority, that an Underpayment has occurred, the 280G Firm will notify the Employee and the Company of that
determination, and the Company will promptly pay the amount of that Underpayment to the Employee. 

  
 13 

 Execution Copy 

 

 (e) The parties will provide the 280G Firm access to and copies of any books, records, and
documents in their possession as reasonably requested by the 280G Firm, and otherwise cooperate with the 280G Firm in connection with the preparation and issuance of the determinations and calculations contemplated by this Section 6.4. 

7. Other Benefits. 
 In
addition to other benefits contained herein, the Employee shall be entitled to the following while Employee is employed with the Company: 

(a) Paid time-off of at least five (5) weeks per year taken in accordance with the paid time-off policy of the Company in effect at the
time. 
 (b) The Company shall provide the Employee with an automobile allowance of $1,000 per month and standard tax preparation and
planning services. 
 8. Confidentiality. 

8.1 The Employee acknowledges that, during the course of performing Employee’s services hereunder, the Company shall be disclosing
information to the Employee related to the Company’s business, Inventions, projects and business plans, as well as other information (collectively, “Confidential Information”). The Employee acknowledges that the Company’s
business is extremely competitive, dependent in part upon the maintenance of secrecy, and that any disclosure of the Confidential Information would result in serious harm to the Company. 

  
 14 

 Execution Copy 

 

 8.2 The Employee agrees that the Confidential Information only shall be used by the Employee
in connection with Employee’s activities hereunder as an employee of the Company, and shall not be used in any way that is detrimental to the Company. 

8.3 The Employee agrees not to disclose, directly or indirectly, the Confidential Information to any third person or entity, other than
representatives or agents of the Company. The Employee shall treat all such information as confidential and proprietary property of the Company. 

8.4 The term “Confidential Information” does not include information that (a) is or becomes generally available to the public
other than by disclosure in violation of this Agreement, (b) was within the Employee’s possession prior to being furnished to such Employee, (c) becomes available to the Employee on a nonconfidential basis or (d) was
independently developed by the Employee without reference to the information provided by the Company. 
 8.5 The Employee may disclose any
Confidential Information that is required to be disclosed by law, government regulation or court order. If disclosure is required, the Employee shall give the Company advance notice so that the Company may seek a protective order or take other
action reasonable in light of the circumstances. 
 8.6 Upon termination of this Agreement, the Employee shall promptly return to the
Company all materials containing Confidential Information, as well as data, records, reports and other property, furnished by the Company to the Employee or produced by the Employee in connection with services rendered hereunder. Notwithstanding
such return or any of the provisions of this Agreement, the Employee shall continue to be bound by the terms of the confidentiality provisions contained in this Section 8 for a period of three (3) years after the termination of this
Agreement. 

  
 15 

 Execution Copy 

 

 8.7 In connection with Employee’s employment by the Company, the Employee hereby
acknowledges that Employee may enter into more than one agreement with regard to (a) the confidentiality of certain books, records, documents and business, (b) rights to certain inventions, proprietary information, and writings,
(c) publication of certain materials, and (d) other related matters (the “Confidential Matters”) of the Company (the “Confidentiality Agreements”). In order to clarify any potential conflicts between certain respective
provisions of such Confidentiality Agreements, the Employee and the Company hereby agree that, as among such Confidentiality Agreements, the provision (or part thereof) in any such Confidentiality Agreement that affords the greatest protection to
the Company with respect to the Confidential Matters shall control. 
 9. Inventions Discovered by the Employee While Performing Services
Hereunder. During the Term, the Employee shall promptly disclose to the Company any invention, improvement, discovery, process, formula, or method or other intellectual property, whether or not patentable, whether or not copyrightable
(collectively, “Inventions”) made, conceived or first reduced to practice by the Employee, either alone or jointly with others, while performing service hereunder. The Employee hereby assigns to the Company all of his right, title and
interest in and to any such Inventions. During and after the Term, the Employee shall execute any documents necessary to perfect the assignment of such Inventions to the Company and to enable the Company to apply for, obtain, and enforce patents and
copyrights in any and all countries on such Inventions. The Employee hereby irrevocably designates the Chief Intellectual Property Officer of the 

  
 16 

 Execution Copy 

 

 
Company as his agent and attorney-in-fact to execute and file any such document and to do all lawful acts necessary to apply for and obtain patents and copyrights and to enforce the
Company’s rights under this paragraph. This Section 9 shall survive the termination of this Agreement. 
 10. Non-Competition
and Non-Solicitation. 
 During the Term and for a period of one year following the date of termination of Employee’s employment
with the Company and/or the termination of this Agreement, for any reason and whether voluntary or involuntary: (a) the Employee shall not in the United States or in any country in which the Company shall then be doing business, directly or
indirectly, enter the employ of, or render any services to, any person, firm or corporation engaged in any business that is competitive with the business of the Company or of any of its subsidiaries or affiliates of which the Employee may become an
employee or officer during the Term; Employee shall not engage in such business on Employee’s own account; and Employee shall not become interested in any such business, directly or indirectly, as an individual, partner, shareholder, director,
officer, principal, agent, employee, trustee, consultant, or any other relationship or capacity; provided, however, that nothing contained in this Section 10 shall be deemed to prohibit the Employee from acquiring, solely as an investment,
shares of capital stock of any public corporation; (b) neither the Employee nor any Affiliate of the Employee shall solicit or utilize, or assist any person in any way to solicit or utilize, the services, directly or indirectly, of any of the
Company’s directors, key advisors, officers or employees (collectively, “Associates of the Company”). This non-solicitation and non-utilization provision shall not apply to Associates of the Company who have previously terminated
their relationship with the Company. The above covenants will apply to the Employee, regardless of the circumstances under which the employment ends or this Agreement is terminated. 

  
 17 

 Execution Copy 

 

 10.1 If the Employee commits a breach, or threatens to commit a breach, of any of the
provisions of this Section 10, the Company shall have the following rights and remedies: 
 10.1.1 The right and remedy to have the
provisions of this Agreement specifically enforced by any court having equity jurisdiction, it being acknowledged and agreed that any such breach or threatened breach shall cause irreparable injury to the Company and that money damages shall not
provide an adequate remedy to the Company; and 
 10.1.2 The right and remedy immediately to cease providing the salary continuation
payments and other benefits under Sections 6.1 and 6.2 of this Agreement and to require the Employee to repay to the Company any such payments and benefits that already have been provided as of the time the Company learns of Employee’s breach
of this Section 10. 
 10.1.3 The right and remedy and to require the Employee to account for and pay over to the Company all
compensation, profits, monies, accruals, increments or other benefits (collectively “Benefits”) derived or received by the Employee as the result of any transactions constituting a breach of any of the provisions of the preceding
paragraph, and the Employee hereby agrees to account for and pay over such Benefits to the Company. 
 Each of the rights and remedies
enumerated above shall be independent of the other, and shall be severally enforceable, and all of such rights and remedies shall be in addition to, and not in lieu of, any other rights and remedies available to the Company under law or in equity.

  
 18 

 Execution Copy 

 

 10.2 If any of the covenants contained in Section 8, 9 or 10, or any part thereof, is
hereafter construed to be invalid or unenforceable, the same shall not affect the remainder of the covenant or covenants, which shall be given full effect without regard to the invalid portions. 

10.3 If any of the covenants contained in Section 8, 9 or 10, or any part thereof, is held to be unenforceable because of the duration
of such provision or the area covered thereby, the parties agree that the court making such determination shall have the power to reduce the duration and/or area of such provision and, in its reduced form, such provision shall then be enforceable.

 10.4 The parties hereto intend to and hereby confer jurisdiction to enforce the covenants contained in Sections 8, 9 and 10 upon the
courts of any state within the geographical scope of such covenants. In the event that the courts of any one or more of such states shall hold any such covenant wholly unenforceable by reason of the breadth of such scope or otherwise, it is the
intention of the parties hereto that such determination not bar or in any way affect the Company’s right to the relief provided above in the courts of any other states within the geographical scope of such covenants, as to breaches of such
covenants in such other respective jurisdictions, the above covenants as they relate to each state being, for this purpose, severable into diverse and independent covenants. 

10.5 The covenants in Sections 8, 9, and 10 are conditions of Employee’s continued employment with the Company, and they are not tied to
Employee’s performance of any particular position, role or job; therefore, the covenants in Sections 8, 9, and 10 shall survive any change in Employee’s position, title, compensation, benefits, role, or responsibilities and

  
 19 

 Execution Copy 

 

 
shall remain in full force and effect following any such change. By continuing in the Company’s employ, Employee continually re-affirms the intention to be bound by these ongoing covenants.

 11. Indemnification. 

The Company shall indemnify the Employee, to the maximum extent permitted by applicable law, against all costs, charges and expenses incurred
or sustained by Employee in connection with any action, suit or proceeding to which Employee may be made a party by reason of being an officer, director or employee of the Company or of any subsidiary or affiliate of the Company. The Company shall
provide, subject to its availability upon reasonable terms (which determination shall be made by the Board) at its expense, directors and officers insurance for the Employee in reasonable amounts. The Board shall make, in its sole discretion,
determination with respect to (a) the availability of insurance upon reasonable terms and (b) the amount of such insurance coverage. 

12. Notices. 
 All
notices, requests, consents and other communications required or permitted to be given hereunder shall be in writing and shall be deemed to have been duly given if sent by prepaid telegram (confirmed delivery by the telegram service), private
overnight mail service (delivery confirmed by such service), registered or certified mail (return receipt requested), or delivered personally, as follows (or to such other address as either party shall designate by notice in writing to the other in
accordance herewith): 

  
 20 

 Execution Copy 

 

 If to the Company: 

ARIAD Pharmaceuticals, Inc. 
 26
Landsdowne Street 
 Cambridge, Massachusetts 02139 

Attention: Chief Executive Officer 

Telephone:      (617) 494-0400 

Fax:                 (617) 494-1828 

If to the Employee: 

Mr. Thomas J. DesRosier 

[Insert] 
 Personal E-mail:
[Insert] 
 Mobile Telephone: [Insert] 

13. General. 
 13.1 This
Agreement shall be governed by and construed and enforced in accordance with the laws of the Commonwealth of Massachusetts applicable to agreements made and to be performed entirely in Massachusetts. 

13.2 The parties agree that any action, claim, or other proceeding involving any dispute between them shall be resolved by a judge alone in a
bench trial, and both parties expressly waive their right to a trial by a jury of any such action, claim, or proceeding. 
 13.3 The
Section headings contained herein are for reference purposes only and shall not in any way affect the meaning or interpretation of this Agreement. 

  
 21 

 Execution Copy 

 

 13.4 This Agreement sets forth the entire agreement and understanding of the parties
relating to the subject matter hereof, and supersedes all prior agreements, arrangements and understandings, written or oral, relating to the subject matter hereof. Neither Party has made any representation, promise or inducement that is not
embodied in this Agreement, and neither party shall be bound by or liable for any alleged representation, promise or inducement not so set forth. 

13.5 This Agreement and the Employee’s rights and obligations hereunder may not be assigned by the Employee or the Company;
provided, however, the Company may assign this Agreement to an Affiliate or a successor-in interest. 
 13.6 This Agreement
may be amended, modified, superseded, canceled, renewed or extended. The terms or covenants hereof may be waived only by a written instrument executed by the parties hereto or in the case of a waiver, by the party waiving compliance. In order to be
effective, any such modification or amendment must be signed by the Company’s Chief Executive Officer; Employee acknowledges that no other officer, employee, Director or representative is authorized to modify or amend the terms of this
Agreement. The failure of a party at any time or times to require performance of any provision hereof shall in no manner affect the right at a later time to enforce the same. No waiver by a party of the breach of any term or covenant contained in
this Agreement, whether by conduct or otherwise, in any one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any such breach, or a waiver of the breach of any other term or covenant contained in this
Agreement. 

  
 22 

 Execution Copy 

 

 14. Section 409A. 

14.1 Notwithstanding any other provision to the contrary, the parties agree that amounts payable under the Agreement shall be interpreted to
comply with or be exempt from Section 409A of the Code (“Section 409A”) consistent with the intentions set forth in this Section 14. 

14.2 Salary continuation payments that may become payable under either Section 6.1 or Section 6.2 are intended to be exempt from
Section 409A to the maximum extent permitted under (a) the “short-term deferral” rule set forth in Section 1.409A-1(b)(4) of the Treasury Regulations (to the extent of such payments made from the date of termination of
employment or termination of the Agreement, as the case may be, through March 14th of the calendar year following such separation) and (b) the “separation pay due to involuntary separation from service” rule set forth in Section
l.409A—1(b)(9)(iii) of the Treasury Regulations (to the extent that such payments made after said March 14th). For purposes of the Agreement, each payable and benefit payable hereunder is intended to constitute a separate payment for
purposes of Section 1.409A-2(b)(2) of the Treasury Regulations. 
 14.3 Continued employer paid COBRA benefits described in
Section 6.1 and 6.2 are intended to be exempt from Section 409A under either the welfare benefits exception set forth in Section 1.409A-1(a)(5) of the Treasury Regulations (if COBRA premium payments are not taxable to the Employee) or
the limited payments exception set forth in Section 1.409A-1(b)(9)(v)(D) of the Treasury Regulations (if COBRA premium payments are taxable to the Employee). 

14.4 All expenses or other reimbursements as provided under the Agreement shall be payable in accordance with the Company’s policies in
effect from time to time, but in any event shall be made 

  
 23 

 Execution Copy 

 

 
on or prior to the last day of the taxable year following the taxable year in which such expenses were incurred by the Employee. No reimbursement or expenses eligible for reimbursement in any
taxable year shall in any way affect the expenses eligible for reimbursement in any other taxable year and the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchanged for another benefit. 

14.5 If the Employee is considered by the Company to be a “specified employee” (within the meaning of Section 409A) upon
separation from service and any payment or the provision of any benefit under the Agreement or otherwise that is payable upon separation from service is determined to be nonqualified deferred compensation subject to Section 409A after giving
full effect to the intentions set forth in this Section 14, then any such payment or benefit shall not commence until the earlier of (i) the first payroll period commencing during the seventh month immediately following the date of such
separation from service, and (ii) the date of Employee’s death (the “Delay Period”). Upon the expiration of the Delay Period, all payments and benefits delayed hereunder (whether they would have otherwise been payable in a single
sum or in installments in the absence of such delay) shall be paid or reimbursed to Employee in a lump sum, and any remaining payments and benefits due under the Agreement shall be paid or provided in accordance with the normal payment dates
specified for them herein. 
 14.6 All payments and benefits that are payable upon a termination of the Agreement (including
Section 6.1) or a termination of the Employee’s employment hereunder shall be paid or provided only upon the Employee’s “separation from service” from the Company within the meaning of Section 409A (determined after
applying the presumptions set forth in Section 1.409A-1(h)(1) of the Treasury Regulations. 

  
 24 

 Execution Copy 

 

 15. Definitions. As used herein the following terms have the following meaning: 

(a) “Affiliate” means and includes any corporation or other business entity controlling, controlled by or under common control with
the corporation in question. 
 (b) “Person” means any natural person, corporation, partnership, firm, joint venture,
association, joint stock company, trust, unincorporated organization, governmental body or other entity. 
 (d) “Subsidiary”
means any corporation or other business entity directly or indirectly controlled by the corporation in question. 
 (e) “Change in
Control” means the occurrence of any of the following events: 
 (i) Any corporation, person or other entity makes a tender or
exchange offer for shares of the Company’s Common Stock pursuant to which such corporation, person or other entity acquires more than fifty (50) percent of the issued and outstanding shares of the Company’s Common Stock; 

(ii) The stockholders of the Company approve a definitive agreement to merge or consolidate the Company with or into another corporation or
to sell or otherwise dispose of all or substantially all of the Company’s assets; or 
 (iii) Any person within the meaning of
Section 3 (a) (9) or Section 13 (d) of the Securities Exchange Act of 1934 acquires more than fifty (50) percent of the combined voting power of Company’s issued and outstanding voting securities entitled to vote
in the election of the Board. 

  
 25 

 Execution Copy 

 

 (f) “Section 409A” means Section 409A of the Internal Revenue Code of 1986,
as amended, and the final regulations and any guidance promulgated thereunder. 
 (g) “Good Reason” means the occurrence of one
or more of the following conditions arising without the Employee’s voluntary consent: 
 (i) any requirement that the
Employee relocate to a worksite that would increase the Employee’s one-way commuting distance by more than twenty-five (25) miles, provided that the Employee gives notice to the Company within ninety (90) days of the relocation and
the increase in commuting distance is not cured within thirty (30) days of such notice; 
 (ii) the Company’s
material breach of any provision of this Agreement with the Employee, provided that the Employee gives notice to the Company within ninety (90) days of the initial occurrence of the breach and it is not cured within thirty (30) days of
such notice; or 
 (iii) the material diminution of Employee’s roles, responsibilities, or scope of authority in the
Company and/or the entity resulting from a Change in Control, provided that the Employee gives notice to the Company within ninety (90) days of the initial occurrence of the material diminution, and it is not cured within thirty (30) days
of such notice. 
 For avoidance of doubt, a “material breach of any provision of this Agreement” under clause (ii) above includes, without
limitation, the 

  
 26 

 Execution Copy 

 

 
Company’s failure to pay or provide salary, bonus or any other form of compensation referenced in Section 3 that is not corrected by the Company within thirty (30) days after
receiving notice from the Employee, provided such notice is provided by the Employee within ninety (90) days of the initial occurrence of the breach. This definition of “Good Reason” shall be interpreted consistent with the definition
of an “involuntary separation from service” under Section 1.409A-1 (n) of the Treasury Regulations. 
 IN WITNESS
WHEREOF, the parties have executed this Agreement as of the date first above written. 
  

			
	ARIAD PHARMACEUTICALS, INC.,
		
	By		 /s/ Harvey J. Berger

			Harvey J. Berger, M.D.
			Chairman and Chief Executive Officer
	
	EMPLOYEE,
	
	 /s/ Thomas J. DesRosier

	Thomas J. DesRosier

  
 27

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00241-of-00352.parquet"}]]